The FDA will convene an advisory committee meeting in September to review Grail’s controversial cancer test after it failed to meet the primary endpoint in a large, randomized trial in the UK. The meeting comes as the company’s test sits at the center of an extended debate over clinical benefit. The decision to schedule an adcomm adds a new procedural milestone for the technology, with regulators and stakeholders likely to revisit study design, endpoint selection, and evidence thresholds for widespread screening.